Core Insights - Profusa, Inc. is set to commercialize its Lumee tissue oxygen monitoring technology in the European Union by early Q2 2026, with plans for U.S. market entry and expanded indications to follow [1][4][6] Revenue Projections - The company anticipates potential revenue of $200 to $250 million by 2030, driven by its Lumee technology and additional indications such as continuous glucose monitoring [2][5] - In 2026, Profusa projects revenue of $0.5 to $2 million from tissue oxygen monitoring in Europe, with a target of $9 to $13 million in 2027 [6][7] Market Potential - The global addressable market for tissue oxygen monitoring is estimated at $10.5 billion, particularly in conditions like peripheral artery disease and critical limb ischemia, with over 716,000 CLI procedures performed annually in Europe [5] - The continuous glucose monitoring market is expected to expand significantly, targeting over 500 million individuals with type 1, type 2, or pre-diabetes worldwide [5] Technological Advancements - Profusa's Lumee technology allows for continuous, real-time measurement of tissue oxygen, providing a less invasive and more convenient experience for patients, while also reducing healthcare costs through improved disease management [3][4] Strategic Partnerships and Distribution - Profusa has established manufacturing capabilities and distributor partnerships, covering approximately 35% of the European population through its intended distribution channels [2][6] - The company plans to layer additional indications onto its Lumee platform over time, including lactate, carbon dioxide, sodium, and ethanol [7]